Elias Chandran

Lutetium-177-PSMA-617: A Vision of the Future

Elias Chandran, William D. Figg, Ravi A. Madan · Cancer Biology & Therapy · 2022 · 27 citations · Full text

Medicine, Oncology, Pharmacology +17

Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors

Andrea B. Apolo, Daniel M. Girardi, Scot A. Niglio et al. · Journal of Clinical Oncology · 2024 · 24 citations · Full text

Medicine, Oncology, Pharmacology +15

Significant Tumor Response to the Poly (ADP-ribose) Polymerase Inhibitor Olaparib in Heavily Pretreated Patient With Ovarian Carcinosarcoma Harboring a Germline RAD51D Mutation

Elias Chandran, Ian M. Kennedy · JCO Precision Oncology · 2018 · 21 citations

Medicine, Oncology, Pharmacology +17

Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers

Andrea B. Apolo, Pavlos Msaouel, Scot A. Niglio et al. · American Society of Clinical Oncology Educational Book · 2022 · 16 citations

Medicine, Oncology, Pharmacology +17

SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.

Andre R. Kydd, Elias Chandran, Nicholas I. Simon et al. · Journal of Clinical Oncology · 2024 · 10 citations

Medicine, Oncology, Pharmacology +17